JP2008063321A - Muscle ageing inhibitor - Google Patents
Muscle ageing inhibitor Download PDFInfo
- Publication number
- JP2008063321A JP2008063321A JP2007186743A JP2007186743A JP2008063321A JP 2008063321 A JP2008063321 A JP 2008063321A JP 2007186743 A JP2007186743 A JP 2007186743A JP 2007186743 A JP2007186743 A JP 2007186743A JP 2008063321 A JP2008063321 A JP 2008063321A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- amino acids
- catechins
- aging
- taurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000032683 aging Effects 0.000 title claims abstract description 63
- 210000003205 muscle Anatomy 0.000 title claims abstract description 61
- 239000003112 inhibitor Substances 0.000 title claims abstract description 24
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 235000005487 catechin Nutrition 0.000 claims abstract description 61
- 150000001413 amino acids Chemical class 0.000 claims abstract description 41
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 36
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 23
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 22
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 22
- 229960003080 taurine Drugs 0.000 claims abstract description 18
- 230000007659 motor function Effects 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 150000001765 catechin Chemical class 0.000 claims description 49
- 235000013361 beverage Nutrition 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 25
- 230000007423 decrease Effects 0.000 claims description 17
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 229950001002 cianidanol Drugs 0.000 abstract description 12
- -1 catechin compound Chemical class 0.000 abstract description 10
- 230000009471 action Effects 0.000 abstract description 6
- 230000003387 muscular Effects 0.000 abstract description 6
- 230000006866 deterioration Effects 0.000 abstract description 2
- 229940024606 amino acid Drugs 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 35
- 244000269722 Thea sinensis Species 0.000 description 29
- 239000000203 mixture Substances 0.000 description 27
- 235000013616 tea Nutrition 0.000 description 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 21
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 21
- 239000000284 extract Substances 0.000 description 18
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 12
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 10
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 10
- 229960000310 isoleucine Drugs 0.000 description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 10
- 239000004474 valine Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000012734 epicatechin Nutrition 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 6
- 208000010428 Muscle Weakness Diseases 0.000 description 6
- 206010028372 Muscular weakness Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 5
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 229940030275 epigallocatechin gallate Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000004220 muscle function Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019225 fermented tea Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 240000008441 Camellia sinensis var. assamica Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000723438 Cercidiphyllum japonicum Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940057106 isoleucine / leucine / valine Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Abstract
Description
本発明は、老化に伴うヒトその他の動物の筋力低下及び筋萎縮の抑制、運動機能の向上並びに寝たきり予防に有効な筋力低下抑制剤、筋萎縮抑制剤、運動機能向上剤及び寝たきり予防剤とその使用に関する。 The present invention relates to suppression of muscle weakness and muscle atrophy in humans and other animals due to aging, improvement of motor function and prevention of bedridden, muscle atrophy inhibitor, motor function improver and bedridden prevention agent, and Regarding use.
老化は生理学的老化と病的老化に大別される。生理的老化は加齢に伴い必然的に起こる老化であり、毛髪、皮膚、眼、骨、筋肉等に変化が生じ、筋肉の重量及び筋力は低下する。 Aging is broadly divided into physiological aging and pathological aging. Physiological aging is aging that inevitably occurs with aging, and changes occur in hair, skin, eyes, bones, muscles, etc., and the weight and strength of muscles decrease.
加齢に伴う筋萎縮や筋力の低下は身体機能を低下させ、寝たきり等の原因となる。また、筋萎縮や筋力の低下を基盤とする日常生活動作中の転倒、及びそれに伴う骨折は、高齢者の主要な寝たきり原因であり、その後のＱＯＬに重大な悪影響をもたらすと考えられる。 Muscle atrophy and muscular strength decrease with aging decrease physical function and cause bedridden. In addition, falls during daily activities based on muscle atrophy and muscular strength, and fractures associated therewith are considered to be a major cause of bedridden elderly people and have a serious adverse effect on the subsequent QOL.
したがって、高齢者の生活機能を改善し健康寿命を延伸するためには、加齢に伴って生じる筋機能の低下を抑制し、運動能力を維持することが重要である。 Therefore, in order to improve the life function of the elderly and extend the healthy life span, it is important to suppress a decrease in muscle function that occurs with aging and maintain exercise ability.
老化は遺伝的要因や環境的要因により進行するが、食事・運動といった生活習慣を始めとする環境的要因を改善することで遅らせることは可能であると考えられている。これまでに運動能力低下を防ぐ手段としては、適度な運動などを実践する、あるいはリハビリテーションを実践する等が挙げられるが、モチベーションの維持の困難さや怪我の恐れもあり、現実的にはなかなか難しく、より効果的な方法が望まれていた。 Although aging progresses due to genetic factors and environmental factors, it is thought that it can be delayed by improving environmental factors including lifestyle habits such as diet and exercise. To date, as a means of preventing athletic ability decline, practice proper exercise, etc., or practice rehabilitation, etc., but there are also difficulties in maintaining motivation and the risk of injury, and in reality it is quite difficult, A more effective method has been desired.
かかる観点から、栄養学的アプローチにより、運動能力を調節しうる成分の探索が行われている。例えば、シスチン及びテアニンによる老化防止（特許文献１）、果実ポリフェノールによる筋萎縮抑制（特許文献２）、リコピンによる筋蛋白分解抑制（特許文献３）、カルボキシル基を２つ以上有する有機酸又はその塩類を有効成分とした運動能力低下抑制（特許文献４）、アスタキサンチン及び／又はそのエステルによる疲労予防剤（特許文献５）、プロアントシアニジンによる筋萎縮抑制剤及び運動能力向上剤（特許文献６、特許文献７）等が開示されている。しかしながら、実際の老化に伴う筋力の低下や筋萎縮に対する効果は検討されていないのが現状である。 From such a point of view, a component capable of adjusting exercise capacity is being searched for by a nutritional approach. For example, prevention of aging by cystine and theanine (Patent Document 1), suppression of muscle atrophy by fruit polyphenol (Patent Document 2), suppression of muscle protein degradation by lycopene (Patent Document 3), organic acid having two or more carboxyl groups or salts thereof An active ingredient that suppresses lowering of athletic ability (Patent Document 4), an anti-fatigue agent with astaxanthin and / or its ester (Patent Document 5), a muscle atrophy inhibitor and an athletic ability improver with proanthocyanidins (Patent Document 6, Patent Document) 7) etc. are disclosed. However, at present, the effect on the decrease in muscle strength and muscle atrophy associated with actual aging has not been studied.
一方、緑茶、紅茶、カカオ豆等に含まれているカテキン類には、コレステロール上昇抑制作用（特許文献８）、血糖上昇阻害作用（特許文献９）、動脈硬化防止作用（特許文献１０）、持久力向上作用（特許文献１１）、筋ジストロフィ抑制作用（非特許文献１）等生理作用があることが知られている。 On the other hand, catechins contained in green tea, black tea, cacao beans, etc. have an inhibitory effect on cholesterol elevation (Patent Document 8), an inhibitory action on blood sugar increase (Patent Document 9), an arteriosclerosis preventive action (Patent Document 10), and endurance. It is known that there are physiological effects such as a force improving action (Patent Document 11) and a muscular dystrophy suppressing action (Non-Patent Document 1).
分岐鎖アミノ酸であるロイシン、バリン及びイソロイシンは耐糖能異常治療薬剤（特許文献１２）、瞬発力・持久的筋力維持剤（特許文献１３）、筋肉痛・筋肉のこりとはり解消剤（特許文献１４）として有用であることが知られている。中でもロイシンは、インスリン分泌促進作用（非特許文献２）や筋タンパク質合成作用（非特許文献３）等の作用が報告されている。しかしながら、カテキン類とアミノ酸類、また両者の併用が老化に伴う筋重量や筋力の低下抑制に及ぼす作用についてはこれまで全く知られていない。
本発明は、優れた筋肉老化抑制作用を示し、筋力低下抑制、筋萎縮抑制、運動機能向上又は寝たきり予防に有効であり、食経験が豊富で安全性の高い医薬品、医薬部外品及び飲食品を提供することに関する。 The present invention has an excellent anti-aging effect on muscle aging, and is effective for suppressing muscle weakness, suppressing muscle atrophy, improving motor function or preventing bedridden, and has abundant dietary experience and a highly safe pharmaceutical, quasi-drug and food and drink Relating to providing.
本発明者らは、上記課題を解決するために鋭意研究を行った結果、カテキン類と分岐鎖アミノ酸及びタウリンから選ばれるアミノ酸類の併用が加齢による筋力低下、筋萎縮抑制作用、運動機能向上及び寝たきり予防を有し、筋肉老化抑制剤等として有用であることを見出した。 As a result of intensive studies to solve the above problems, the present inventors have found that the combined use of catechins and amino acids selected from branched chain amino acids and taurine reduces muscle strength due to aging, suppresses muscle atrophy, and improves motor function. It has also been found that it has bedridden prevention and is useful as a muscle aging inhibitor and the like.
すなわち、本発明は、（ａ）カテキン類、並びに（ｂ）分岐鎖アミノ酸及びタウリンから選ばれるアミノ酸類を有効成分とする筋肉老化抑制剤を提供するものである。
また本発明は、（ａ）カテキン類、並びに（ｂ）分岐鎖アミノ酸及びタウリンから選ばれるアミノ酸類を有効成分とする運動機能向上剤を提供するものである。
また本発明は、（ａ）カテキン類、並びに（ｂ）分岐鎖アミノ酸及びタウリンから選ばれるアミノ酸類を有効成分とする寝たきり予防剤を提供するものである。
また本発明は、（ａ）カテキン類、並びに（ｂ）分岐鎖アミノ酸及びタウリンから選ばれるアミノ酸類を含有する筋力老化抑制用飲食品、運動機能向上用飲食品又は寝たきり予防用飲食品を提供するものである。
更に本発明は、（ａ）カテキン類、並びに（ｂ）分岐鎖アミノ酸及びタウリンから選ばれるアミノ酸類の筋肉老化抑制剤、運動機能向上剤又は寝たきり予防剤としての使用を提供するものである。
That is, the present invention provides a muscle aging inhibitor comprising (a) catechins and (b) amino acids selected from branched chain amino acids and taurine as active ingredients.
The present invention also provides a motor function improver comprising as an active ingredient an amino acid selected from (a) catechins and (b) branched chain amino acids and taurine.
The present invention also provides a bedridden prevention agent comprising (a) catechins and (b) amino acids selected from branched chain amino acids and taurine as active ingredients.
The present invention also provides (a) catechins, and (b) foods and drinks for suppressing muscle aging, foods and drinks for improving motor function, and foods and drinks for bedridden prevention containing amino acids selected from branched chain amino acids and taurine. Is.
Furthermore, the present invention provides the use of (a) catechins and (b) amino acids selected from branched chain amino acids and taurine as muscle aging inhibitors, motor function improvers or bedridden preventing agents.
本発明の筋肉老化抑制剤、筋力低下抑制剤、筋萎縮抑制剤又は寝たきり予防剤は、長期間投与又は摂取しても安全性が高いカテキン類及び特定のアミノ酸類を有効成分とするものであり、加齢に伴い生じる筋力の低下や筋萎縮を抑制する効果を発揮する飲食品、医薬品等として有用である。また本発明の運動機能向上剤は筋力等の運動機能を向上させる作用を有する飲食品、医薬品等として有用である。 The muscle aging inhibitor, muscle weakness inhibitor, muscle atrophy inhibitor or bedridden preventing agent of the present invention comprises catechins and specific amino acids that are highly safe even when administered or ingested for a long time as active ingredients. It is useful as a food and drink, a pharmaceutical product, and the like that exhibit the effect of suppressing the decrease in muscle strength and muscle atrophy caused by aging. In addition, the motor function improver of the present invention is useful as a food or drink, a pharmaceutical product or the like having an effect of improving a motor function such as muscle strength.
本発明において、「筋萎縮」とは、筋細胞の減少や縮小により筋量が低下することをいい、長期間の安静臥床や骨折などによるギプス固定、あるいは微小重力暴露によるもの（廃用性筋萎縮という。）、加齢（老化ともいう）に伴うもの（サルコペニアという。）が挙げられる。したがって「筋萎縮の抑制」とは、不活動や加齢に伴う筋量の低下を抑制することを指す。
また、「筋肉老化」とは、加齢に伴って生じる筋肉の衰え、例えば筋機能低下や筋萎縮を指す。「運動機能向上」とは、筋機能（筋力）の低下を抑制させることによって運動能力を維持又は向上することを指す。
また、本発明において、「筋機能低下」とは、筋萎縮に伴って、筋が構造的あるいは質的に変化し、筋力、筋持久力、筋瞬発力が低下することを示す。したがって「筋機能低下の抑制」とは、筋力、筋持久力、筋瞬発力の低下を抑制することを指す。
また、「寝たきり」とは、特に老化、例えば３０代以降の中高年においてみられる廃用性筋萎縮とサルコペニアとが複合した症状、例えば、高齢者の脳卒中や骨折等の治療や療養等において運動量が極度に少なくなり、さらに筋機能が低下し、寝かせきり状態からつくられるものを指す。
In the present invention, “muscle atrophy” refers to a decrease in muscle mass due to a decrease or decrease in muscle cells, such as cast fixation by prolonged bed rest or fracture, or exposure to microgravity (disused muscles). And atrophy associated with aging (also referred to as aging) (referred to as sarcopenia). Therefore, “suppression of muscle atrophy” refers to suppressing the decrease in muscle mass associated with inactivity and aging.
“Muscle aging” refers to muscle weakening that occurs with aging, such as muscle function decline and muscle atrophy. “Improvement of motor function” refers to maintaining or improving motor ability by suppressing a decrease in muscle function (muscle strength).
In the present invention, “muscle function decrease” means that muscles structurally or qualitatively change with muscle atrophy, resulting in a decrease in muscle strength, muscle endurance, and instantaneous power. Therefore, “suppression of muscle function deterioration” refers to suppression of reduction in muscle strength, muscle endurance, and instantaneous power.
In addition, “bedridden” refers to a combination of disuse muscular atrophy and sarcopenia, such as those seen in middle-aged and older adults, for example, aging, such as stroke and fracture of the elderly and treatment, etc. It refers to those that are made extremely low, muscular function declines, and are laid down.
本発明における（ａ）カテキン類とは、カテキン、カテキンガレート、ガロカテキン及びガロカテキンガレート等の非エピ体カテキン類並びに、エピカテキン、エピガロカテキン、エピカテキンガレート及びエピガロカテキンガレート等のエピ体カテキン類の総称であり、これらの一種以上を含有するのが好ましい。また、カテキン類は、非重合体であるのが好ましい。 In the present invention, (a) catechins means non-epimeric catechins such as catechin, catechin gallate, gallocatechin and gallocatechin gallate, and epicatechins such as epicatechin, epigallocatechin, epicatechin gallate and epigallocatechin gallate It is a generic name of a class and preferably contains one or more of these. The catechins are preferably non-polymers.
本発明に使用するカテキン類は、一般的には茶葉から直接抽出すること、又はその茶抽出物を濃縮若しくは精製することにより得ることができるが、他の原料由来のもの、カラム精製品及び化学合成品でもあってもよい。 The catechins used in the present invention can generally be obtained by direct extraction from tea leaves or by concentrating or purifying the tea extract, but those derived from other raw materials, column purified products and chemicals It may be a synthetic product.
当該茶抽出は、Camellia属、例えばC. sinensis、C. assamica、又はそれらの雑種から得られる茶葉から製茶された茶葉に、水又は熱水やこれらに抽出助剤を添加し、攪拌抽出等をすることにより行うことができる。また、煮沸脱気や窒素ガス等の不活性ガスを通気して溶存酸素を除去しつつ、いわゆる非酸化的雰囲気下で抽出する方法を併用してもよい。抽出助剤としては、アスコルビン酸ナトリウム等の有機酸、又はこれら有機酸塩類が挙げられる。
当該製茶された茶葉には、（１）煎茶、番茶、玉露、てん茶、釜煎り茶等の緑茶類；（２）総称して烏龍茶と呼ばれる鉄観音、色種、黄金桂、武夷岩茶等の半発酵茶；（３）紅茶と呼ばれるダージリン、ウバ、キーマン等の発酵茶が含まれる。
The tea extraction is carried out by adding water or hot water or an extraction aid to these tea leaves made from tea leaves obtained from the genus Camellia, such as C. sinensis, C. assamica, or hybrids thereof, followed by stirring extraction, etc. This can be done. Moreover, you may use together the method of extracting in so-called non-oxidative atmosphere, ventilating inert gas, such as boiling deaeration and nitrogen gas, and removing dissolved oxygen. Examples of the extraction aid include organic acids such as sodium ascorbate or organic acid salts thereof.
The tea leaves produced are: (1) Green teas such as Sencha, Bancha, Gyokuro, Tencha, Kamasencha; (2) Iron Kannon, color types, golden katsura, wushuiwa tea, etc. (3) Fermented teas such as Darjeeling, Uba, and Keyman called black tea are included.
当該茶抽出物の濃縮は、上記抽出物を濃縮することにより行うことができ、当該茶抽出物の精製は、溶剤やカラムを用いて精製することにより行うことができる。茶抽出物の濃縮物や精製物の形態としては、固体、水溶液、スラリー状等種々のものが挙げられる。
例えば、当該茶抽出物は、特開昭５９−２１９３８４号、特開平４−２０５８９号、特開平５−２６０９０７号、特開平５−３０６２７９号等に詳細に例示されている方法で調製することができる。また、市販品を用いることもでき、斯かる市販品としては、三井農林（株）「ポリフェノン」、（株）伊藤園「テアフラン」、太陽化学（株）「サンフェノン」、サントリー（株）「サンウーロン」等が挙げられる。
Concentration of the tea extract can be performed by concentrating the extract, and purification of the tea extract can be performed by purification using a solvent or a column. Various forms such as a solid, an aqueous solution, and a slurry are exemplified as the form of the concentrate or purified product of the tea extract.
For example, the tea extract can be prepared by a method exemplified in detail in JP-A-59-219384, JP-A-4-20589, JP-A-5-260907, JP-A-5-306279, and the like. it can. Commercial products can also be used, such as Mitsui Norin Co., Ltd. “Polyphenone”, ITO EN “Teafuran”, Taiyo Kagaku Co., Ltd. “Sunphenon”, Suntory Co., Ltd. Or the like.
当該茶抽出物中のカテキン類は、非重合体で存在し、かつ液に溶解しているもの又は茶の微細粉末の懸濁物に吸着若しくは包含された固形状のものとして存在する。
また、当該抽出物中のカテキン類の含有量は、３０〜９８質量％、好ましくは４０〜９０質量％である。また、これらの総ポリフェノール中のカテキン類の含有率は、製造直後でカテキン量が１０質量％以上で、好ましくは２０質量％以上である。
The catechins in the tea extract are present as non-polymers and dissolved in a liquid or as solids adsorbed or included in a suspension of fine tea powder.
Moreover, content of the catechin in the said extract is 30-98 mass%, Preferably it is 40-90 mass%. Moreover, the content rate of catechins in these total polyphenols is 10 mass% or more in the amount of catechin immediately after manufacture, Preferably it is 20 mass% or more.
また、茶葉中のカテキン類の大部分はエピ体カテキン類として存在しており、このエピ
体カテキン類を用いて熱や酸やアルカリ等の処理により立体異性体である非エピ体に変化させることができる。従って、非エピ体カテキン類を使用する場合には、緑茶類、半発酵茶類又は発酵茶類からの抽出液や茶抽出液の濃縮物を水溶液にして、例えば４０〜１４０℃、０．１分〜１２０時間加熱処理して得ることができる。また非エピカテキン類含有量の高い茶抽出液の濃縮物を使用してもよい。それらは単独又は併用してもよい。
In addition, most of the catechins in tea leaves exist as epi-catechins, and these epi-catechins can be converted to non-epi-isomers that are stereoisomers by treatment with heat, acid, alkali, etc. Can do. Accordingly, when non-epimeric catechins are used, an extract from green tea, semi-fermented tea or fermented tea or a concentrate of tea extract is made into an aqueous solution, for example, 40 to 140 ° C., 0.1 It can be obtained by heat treatment for min to 120 hours. Moreover, you may use the concentrate of the tea extract with high non-epicatechin content. They may be used alone or in combination.
本発明に用いる（ｂ）アミノ酸類のうち、分岐鎖アミノ酸とは、構造上に分岐鎖をもつアミノ酸で、このうち、ロイシン、イソロイシン、バリンが好ましい。本発明においてはバリン、ロイシン、イソロイシン、タウリンのうち少なくとも１種をカテキン類と共に使用するのが好ましい。入手方法としては、市販品を用いても良く、公知の方法に基づき製造することも可能である。 Among the amino acids (b) used in the present invention, the branched chain amino acid is an amino acid having a branched chain in structure, and among these, leucine, isoleucine and valine are preferable. In the present invention, it is preferable to use at least one of valine, leucine, isoleucine and taurine together with catechins. As an obtaining method, a commercially available product may be used, or it can be produced based on a known method.
本発明にかかる有効成分として使用する（ｂ）アミノ酸類の異性体に関しては、Ｌ−体、Ｄ−体、ＤＬ−体のいずれの異性体も使用可能である。しかしながら、天然に存在する観点からＬ−体が好ましい。 Regarding the isomer of (b) amino acids used as the active ingredient according to the present invention, any of the L-isomer, D-isomer, and DL-isomer can be used. However, the L-form is preferred from the viewpoint of existing in nature.
本発明の（ａ）カテキン類及び（ｂ）前記アミノ酸類の組み合せは、後記実施例に示されるように、（ａ）カテキン類又は（ｂ）前記アミノ酸類をそれぞれ単独の場合に比べて顕著に優れた加齢による筋力低下抑制作用や筋萎縮抑制作用並びに運動機能向上作用を有することから、ベッドレスト者や高齢者、運動不足者における筋力低下抑制剤、筋萎縮抑制剤及び寝たきり予防剤として使用できるのみならず、あらゆる人々の老化に対処するために用いることができる。そして、当該筋肉老化抑制剤、筋力低下抑制剤、筋萎縮抑制剤、運動機能向上剤又は寝たきり予防剤（以下、筋肉老化抑制剤等とする。）は、各効果を発揮する、ヒト若しくは動物用の医薬品、医薬部外品、飲食品として使用可能である。 The combination of (a) catechins and (b) the amino acids of the present invention is remarkably compared to the case where (a) catechins or (b) the amino acids are used alone, as shown in Examples below. Because it has excellent aging-induced muscle weakness-inhibiting effect, muscle atrophy-inhibiting effect, and motor function-improving effect, it is used as a muscle weakness-inhibiting agent, muscle atrophy-inhibiting agent, and bedridden-preventing agent in bed resters, elderly people, and those with exercise deficiencies. Not only can it be used to deal with the aging of all people. The muscle aging inhibitor, muscle weakness inhibitor, muscle atrophy inhibitor, motor function improver, or bedridden preventive agent (hereinafter referred to as muscle aging inhibitor, etc.) is used for humans or animals that exhibit each effect. It can be used as pharmaceuticals, quasi-drugs, and foods.
本発明にかかる組成物には、医薬品、医薬部外品、飲食品の形態で使用する場合、本発明の（ａ）カテキン類及び（ｂ）前記アミノ酸類以外に他の成分を併用、使用することができる。例えば、必要に応じてアルギニン、グリシン、リジン、アラニン、シスチン、システイン、チアニン、メチオニン等のその他のアミノ酸、ビタミン類、カルノシン等のジペプチド類、無機塩類、医薬品や医薬部外品、飲食品に通常含有せしめる補助的成分を任意に添加することができる。 In the composition according to the present invention, when used in the form of pharmaceuticals, quasi-drugs, and foods and drinks, other components are used in combination with (a) catechins and (b) the amino acids of the present invention. be able to. For example, arginine, glycine, lysine, alanine, cystine, cysteine, thianine, methionine and other amino acids, vitamins, carnosine and other dipeptides, inorganic salts, pharmaceuticals and quasi drugs, food and drink An auxiliary component to be contained can be optionally added.
本発明にかかる組成物は、医薬品として、錠剤及び粉末のような固形投薬形態、あるいはエリキシロール、シロップ及び懸濁液のような液体投薬形態で経口投与される。経口投与薬として使用する場合の補助剤としては、例えば固形粉末状の担体、グルコース、ラクトース、サッカロースなどの糖、セルロース等が挙げられる。潤滑剤として二酸化珪素、タルク、ステアリン酸マグネシウム、ポリエチレングリコール等、結合剤としてデンプン、ゼラチン、メチルセルロース、ポリビニルピロリドン等が例示できる。崩壊剤としてはデンプン、寒天等がある。 The compositions according to the invention are administered orally as pharmaceuticals in solid dosage forms such as tablets and powders or liquid dosage forms such as elixirol, syrups and suspensions. Examples of adjuvants used as orally administered drugs include solid powder carriers, sugars such as glucose, lactose and saccharose, and cellulose. Examples of the lubricant include silicon dioxide, talc, magnesium stearate, and polyethylene glycol, and examples of the binder include starch, gelatin, methyl cellulose, and polyvinyl pyrrolidone. Disintegrants include starch and agar.
また、本発明にかかる組成物は、適当量の栄養補給が困難な高齢者やベッドレスト状態の病者においては、経腸栄養剤等の栄養組成物の形態で投与される。 In addition, the composition according to the present invention is administered in the form of a nutritional composition such as an enteral nutrient for elderly people who are difficult to supplement with an appropriate amount of nutrition or who are in bed rest.
このような栄養組成物の一例として、蛋白質（蛋白質源としてはアミノ酸バランスのとれた栄養価の高い乳蛋白質、大豆蛋白質、卵アルブミン等の蛋白質が最も広く使用されるが、これらの分解物、卵白のオリゴペプチド、大豆加水分解物等も使用される）、糖類、脂肪、微量元素、ビタミン類、乳化剤、香料等が配合された栄養組成物が挙げられる。本栄養組成物は、原料を適当な溶媒に溶解、混合した後、ホモジナイザー等で均質化し、容器に充填したのちレトルト殺菌等により殺菌することによって、液状の製剤を得ることができる。また、噴霧乾燥等により、これを粉末状の製剤とすることもできる。 As an example of such a nutritional composition, proteins (proteins such as milk proteins with high amino acid balance, soy protein, egg albumin and the like are most widely used as protein sources. Oligopeptides, soybean hydrolysates, etc.), saccharides, fats, trace elements, vitamins, emulsifiers, fragrances and the like. The nutritional composition can be obtained by dissolving and mixing the raw materials in a suitable solvent, homogenizing with a homogenizer or the like, filling the container, and sterilizing by retort sterilization or the like to obtain a liquid preparation. It can also be made into a powdery formulation by spray drying or the like.
本発明の有効成分として投与される（ａ）カテキン類の量は、投与される患者の性別、年齢、体重、症状の程度等によって異なるが、成人に対して１日あたり、１００〜３０００ｍｇ／６０ｋｇ体重とするのが好ましく、特に２５０〜２０００ｍｇ／６０ｋｇ体重、更に２５０〜１０００ｍｇ／６０ｋｇ体重とするのが好ましい。 The amount of (a) catechins administered as an active ingredient of the present invention varies depending on the sex, age, weight, symptom level, etc. of the patient to be administered, but is 100 to 3000 mg / 60 kg per day for an adult. The body weight is preferable, in particular, 250 to 2000 mg / 60 kg body weight, more preferably 250 to 1000 mg / 60 kg body weight.
本発明の有効成分として投与される（ｂ）前記アミノ酸類の総量は、投与される患者の性別、年齢、体重、症状の程度等によって異なるが、成人に対して１日あたり、１００〜６００００ｍｇ／６０ｋｇ体重とするのが好ましく、特に５００〜２００００ｍｇ／６０ｋｇ体重、更に１０００〜６０００ｍｇ／６０ｋｇ体重とするのが好ましい。分岐鎖アミノ酸については、ロイシンは１日当たり３００ｍｇ〜２００００ｍｇ含有することが好ましく、５００〜４０００ｍｇ含有するのが更に好ましい。イソロイシンは３００ｍｇ〜２００００ｍｇ含有することが好ましく、５００〜３０００ｍｇ含有するのが更に好ましい。バリンは３００〜２００００ｍｇ含有することが好ましく、５００〜３０００ｍｇ含有するのが更に好ましい。タウリンは１日当たり３００〜１００００ｍｇ投与することが好ましく、５００〜３０００ｍｇ投与することが更に好ましい。 (B) The total amount of the amino acids to be administered as an active ingredient of the present invention varies depending on the sex, age, weight, symptom level, etc. of the patient to be administered, but it is 100 to 60000 mg / day for an adult. The weight is preferably 60 kg, particularly 500 to 20000 mg / 60 kg, and more preferably 1000 to 6000 mg / 60 kg. As for the branched chain amino acid, leucine is preferably contained in an amount of 300 mg to 20000 mg, more preferably 500 to 4000 mg per day. Isoleucine is preferably contained in an amount of 300 mg to 20000 mg, more preferably 500 to 3000 mg. The valine content is preferably 300 to 20000 mg, more preferably 500 to 3000 mg. Taurine is preferably administered in an amount of 300 to 10,000 mg per day, more preferably 500 to 3000 mg.
本発明の有効成分として組成物中に含まれる分岐鎖アミノ酸は、イソロイシン、ロイシン及びバリンの混合物を使用することが好ましい。この場合、イソロイシン：ロイシン：バリンの重量配合比においてイソロイシン／ロイシン／バリン＝１〜１．１／１．９〜２．２／１〜１．３となるような組成範囲で使用することがより好ましい。 As the branched chain amino acid contained in the composition as the active ingredient of the present invention, it is preferable to use a mixture of isoleucine, leucine and valine. In this case, isoleucine / leucine: valine in a weight blending ratio of isoleucine / leucine / valine = 1 to 1.1 / 1.9 to 2.2 / 1 to 1.3 may be used in a composition range. preferable.
また、本発明の飲食品の形態としては、チーズ（ナチュラル、プロセス）、アイスクリーム、ヨーグルト、その他乳製品、ソース、スープ、ふりかけ、和菓子類（せんべい等）、洋菓子類（ポテトチップス、プリン、ゼリー、グミキャンディー、キャンディー、ドロップ、キャラメル、チョコレート、チューインガム等）、焼き菓子類（カステラ、ケーキ、ドーナッツ、ビスケット、クッキー、クラッカー等）、炭酸系飲料、非炭酸系飲料（果汁飲料、ネクター飲料等）、清涼飲料、スポーツ飲料、ニアウォーター、茶、コーヒー、ココアなど非アルコール飲料等の一般食品の形態を挙げることができる。本発明の飲食品は、カテキン類及びアミノ酸類を一般食品の原料とともに配合し、通常の方法により加工製造することができる。 The form of the food and drink of the present invention includes cheese (natural, process), ice cream, yogurt, other dairy products, sauce, soup, sprinkle, Japanese confectionery (such as rice crackers), and Western confectionery (potato chips, pudding, jelly). , Gummy candy, candy, drop, caramel, chocolate, chewing gum, etc.), baked confectionery (castella, cake, donuts, biscuits, cookies, crackers, etc.), carbonated drinks, non-carbonated drinks (fruit juice drinks, nectar drinks, etc.) Examples of general foods such as non-alcoholic drinks such as soft drinks, sports drinks, near water, tea, coffee, and cocoa can be given. The food / beverage products of this invention can mix | blend catechins and amino acids with the raw material of general food, and can process and manufacture it by a normal method.
例えば、本発明の飲料は、長期摂取できる味及び安定性、並びに効果の点から、カテキン類を、飲料５００ｍＬ当り合計量５０〜２５００ｍｇ含有するが、好ましくは２００〜２５００ｍｇ、より好ましくは３００〜１３００ｍｇ、更に好ましくは４００〜１０００ｍｇ含有するのが、味の点から好ましい。
また、（ａ）カテキン類の含有量の３０〜９８重量％、好ましくは４０〜９０重量％が、エピガロカテキンガレート、ガロカテキンガレート、エピガロカテキン、ガロカテキンから選ばれたものであると、飲料としての呈味が更に優れ、後を引くような収斂性も少なく好ましい。ここでエピガロカテキンガレート、ガロカテキンガレート、エピガロカテキン、ガロカテキンは１種以上含有するが、通常は全て含有される。
For example, the beverage of the present invention contains catechins in a total amount of 50 to 2500 mg per 500 mL of beverage from the viewpoint of taste and stability that can be ingested over a long period of time, and effects, but preferably 200 to 2500 mg, more preferably 300 to 1300 mg. Furthermore, it is more preferable from the point of taste to contain 400-1000 mg.
(A) 30 to 98% by weight, preferably 40 to 90% by weight of the content of catechins is selected from epigallocatechin gallate, gallocatechin gallate, epigallocatechin, and gallocatechin The taste is further excellent, and the astringency that pulls behind is also low, which is preferable. Here, one or more types of epigallocatechin gallate, gallocatechin gallate, epigallocatechin, and gallocatechin are contained, but usually all are contained.
また、本発明の飲料は、（ａ）カテキン類に加え、（ｂ）前記アミノ酸類を、飲料５００ｍＬ当り合計量１００〜６００００ｍｇ含有するが、５００〜２００００ｍｇが好ましく、５００〜１００００ｍｇがより好ましく、１０００〜６０００ｍｇ含有するのが更に好ましい。
各アミノ酸については、ロイシンは飲料５００ｍＬ当たり１００ｍｇ〜２００００ｍｇ含有することが好ましく、５００〜４０００ｍｇ含有するのが更に好ましい。イソロイシンは１００ｍｇ〜２００００ｍｇ含有することが好ましく、５００〜３０００ｍｇ含有するのが更に好ましい。バリンは１００〜２００００ｍｇ含有することが好ましく、５００
〜３０００ｍｇ含有するのが更に好ましい。タウリンは１００〜１００００ｍｇ含有することが好ましく、５００〜３０００ｍｇ含有するのが更に好ましい。
In addition to (a) catechins, the beverage of the present invention contains (b) the amino acids in a total amount of 100 to 60000 mg per 500 mL of beverage, preferably 500 to 20000 mg, more preferably 500 to 10000 mg, 1000 More preferably, it contains ˜6000 mg.
About each amino acid, it is preferable to contain 100 mg-20000 mg of leucine per 500 mL of drinks, and it is still more preferable to contain 500-4000 mg. Isoleucine is preferably contained in an amount of 100 mg to 20000 mg, more preferably 500 to 3000 mg. The valine is preferably contained in an amount of 100 to 20000 mg, 500
It is more preferable to contain -3000 mg. Taurine is preferably contained in an amount of 100 to 10,000 mg, more preferably 500 to 3000 mg.
飲料のｐＨは、２５℃で３〜７、好ましくは４〜７、特に５〜７とするのが、味及びカテキン類の化学的安定性の点で好ましい。 The pH of the beverage is preferably 3 to 7, preferably 4 to 7, particularly 5 to 7 at 25 ° C. in terms of taste and chemical stability of catechins.
本発明の飲料には、茶由来の（ａ）カテキン類成分及び（ｂ）前記アミノ酸類の他、酸化防止剤、香料、各種エステル類、有機酸類、有機酸塩類、無機酸類、無機酸塩類、無機塩類、色素類、乳化剤、保存料、調味料、甘味料、酸味料、果汁エキス類、野菜エキス類、花蜜エキス類、ビタミン類、ｐＨ調整剤、品質安定剤等を単独、あるいは併用して配合しても良い。 The beverage of the present invention includes tea-derived (a) catechin components and (b) the above amino acids, antioxidants, fragrances, various esters, organic acids, organic acid salts, inorganic acids, inorganic acid salts, Inorganic salts, pigments, emulsifiers, preservatives, seasonings, sweeteners, acidulants, fruit juice extracts, vegetable extracts, nectar extracts, vitamins, pH adjusters, quality stabilizers, etc. alone or in combination You may mix.
本発明の筋肉老化抑制剤等は果汁などの他の飲料成分と組み合わせることで、例えば茶系飲料、炭酸飲料、果実エキス入り飲料、野菜エキス入りジュースや、ニアウォーター、スポーツ飲料、ダイエット飲料などを提供することが可能である。
また本発明においては、長時間保存時に安定した色調と外観の透明性を呈する飲料に、消費者の嗜好にあわせて茶葉の微粉末のような不溶性化合物をあえて懸濁させた形態の飲料も可能である。尚、本発明の飲料において必ずしも有効成分が溶解している必要はない。
The muscle aging inhibitor of the present invention is combined with other beverage components such as fruit juice, for example, tea beverages, carbonated beverages, fruit extract beverages, vegetable extract juices, near water, sports beverages, diet beverages, etc. It is possible to provide.
In addition, in the present invention, a beverage having a stable color tone and transparency of appearance when stored for a long period of time and a beverage in which an insoluble compound such as a fine powder of tea leaves is intentionally suspended according to consumer's preference is also possible It is. In addition, the active ingredient does not necessarily need to be dissolved in the beverage of the present invention.
飲料として飲用する場合には、使用される容器は、一般の飲料と同様にポリエチレンテレフタレートを主成分とする成形容器（いわゆるＰＥＴボトル）、金属缶、金属箔やプラスチックフィルムと複合された紙容器、瓶などの通常の形態で提供することができる。ここでいう飲料とは希釈せずに飲用できるものをいう。 When drinking as a beverage, the container used is a molded container (so-called PET bottle) containing polyethylene terephthalate as the main component, a metal can, a paper container combined with a metal foil or a plastic film, as with a general beverage, It can be provided in a conventional form such as a bottle. A drink here means what can be drunk without dilution.
また本発明の飲料は、例えば、金属缶のように容器に充填後、加熱殺菌できる場合にあっては食品衛生法に定められた殺菌条件で製造される。ＰＥＴボトル、紙容器のようにレトルト殺菌できないものについては、あらかじめ上記と同等の殺菌条件、例えばプレート式熱交換器などで高温短時間殺菌後、一定の温度まで冷却して容器に充填する等の方法が採用される。また無菌下で、充填された容器に別の成分を配合して充填してもよい。更に、酸性下で加熱殺菌後、無菌下でｐＨを中性に戻すことや、中性下で加熱殺菌後、無菌下でｐＨを酸性に戻すなどの操作も可能である。 Moreover, the drink of this invention is manufactured on the sterilization conditions prescribed | regulated to the food hygiene law, for example, when it can heat-sterilize after filling a container like a metal can. For PET bottles and paper containers that cannot be sterilized by retort, sterilize under the same conditions as above, for example, after sterilizing at high temperature and short time with a plate heat exchanger, etc. The method is adopted. Moreover, you may mix | blend another component with the filled container under aseptic conditions. Furthermore, after sterilizing under heat, the pH can be returned to neutral under aseptic conditions, or after sterilizing under heat under neutral conditions, the pH can be returned to acidic conditions under aseptic conditions.
非飲料製剤中の（ａ）カテキン類の配合量は、その使用形態により異なるが、食品やペットフード等の場合、通常０．０１〜５重量％、更に０．０５〜５重量％、特に０．１〜１重量％とするのが好ましい。上記以外の医薬品、例えば錠剤、顆粒剤、カプセル剤等の経口用固形製剤、内服液剤、シロップ剤等の経口用液体製剤等の場合、通常０．０１〜９５重量％、更に５〜９０重量％、特に１０〜８０重量％とするのが好ましい。 The blending amount of (a) catechins in the non-beverage preparation varies depending on the form of use, but in the case of food or pet food, it is usually 0.01 to 5% by weight, more preferably 0.05 to 5% by weight, especially 0 0.1 to 1% by weight is preferable. In the case of pharmaceuticals other than the above, such as oral solid preparations such as tablets, granules and capsules, oral liquid preparations such as oral liquids and syrups, etc., usually 0.01 to 95% by weight, more preferably 5 to 90% by weight In particular, it is preferably 10 to 80% by weight.
非飲料製剤中に（ａ）カテキン類に加えて配合される（ｂ）前記アミノ酸類の量は、その使用形態により異なるが、食品やペットフード等の場合、通常０．０１〜５重量％、更に０．１〜５重量％、特に０．２〜２重量％とするのが好ましい。上記以外の医薬品、例えば錠剤、顆粒剤、カプセル剤等の経口用固形製剤、内服液剤、シロップ剤等の経口用液体製剤等の場合、通常０．０１〜９５重量％、更に５〜９０重量％、特に１０〜８０重量％とするのが好ましい。 In the non-beverage preparation, (a) the amount of the amino acids blended in addition to the catechins varies depending on the use form, but in the case of food or pet food, usually 0.01 to 5% by weight, Furthermore, it is preferable to set it as 0.1 to 5 weight%, especially 0.2 to 2 weight%. In the case of pharmaceuticals other than the above, such as oral solid preparations such as tablets, granules and capsules, oral liquid preparations such as oral liquids and syrups, etc., usually 0.01 to 95% by weight, more preferably 5 to 90% by weight In particular, it is preferably 10 to 80% by weight.
本発明の食品による（ａ）カテキン類の投与量（有効摂取量）は、一日当り１００〜３０００ｍｇ／６０ｋｇ体重とするのが好ましく、特に２５０〜２０００ｍｇ／６０ｋｇ体重、更に２５０〜１０００ｍｇ／６０ｋｇ体重とするのが好ましい。投与量は、投与され
る患者の性別、年齢、体重、症状の程度等によって異なることは明らかである。
The dose (effective intake amount) of (a) catechins by the food of the present invention is preferably 100 to 3000 mg / 60 kg body weight per day, particularly 250 to 2000 mg / 60 kg body weight, more preferably 250 to 1000 mg / 60 kg body weight. It is preferable to do this. It is obvious that the dose varies depending on the sex, age, weight, degree of symptoms, etc. of the patient to be administered.
本発明の食品による（ｂ）前記アミノ酸類の投与量（有効摂取量）は、１日あたり、１００〜６００００ｍｇ／６０ｋｇ体重とするのが好ましく、特に５００〜２００００ｍｇ／６０ｋｇ体重、更に１０００〜６０００ｍｇ／６０ｋｇ体重とするのが好ましい。 The dose (effective intake) of the amino acids (b) by the food of the present invention is preferably 100 to 60000 mg / 60 kg body weight per day, particularly 500 to 20000 mg / 60 kg body weight, more preferably 1000 to 6000 mg / day. 60 kg body weight is preferred.
以下、本発明を更に詳しく説明するため、本発明組成物につき行った試験例を挙げ、次いで本発明組成物の調製例を実施例として挙げる。 Hereinafter, in order to explain the present invention in more detail, test examples performed on the composition of the present invention are given, and then, preparation examples of the composition of the present invention are given as examples.
試験例１ （ａ）カテキン類及び（ｂ）前記アミノ酸類の筋肉老化抑制効果
（ａ）カテキン類として、総カテキン量８１％の茶抽出物を用いた。また、カテキン類の組成は、ガロカテキン（７％）、ガロカテキンガレート（４％）、エピカテキン（９％）、エピガロカテキン（２３％）、エピカテキンガレート（１２％）、エピガロカテキンガレート（４１％）、その他（４％）であった。また、（ｂ）アミノ酸類として、ロイシンを用いた。
Test Example 1 (a) Catechins and (b) Muscle aging inhibitory effect of the amino acids (a) As catechins, a tea extract having a total catechin amount of 81% was used. The composition of catechins is as follows: gallocatechin (7%), gallocatechin gallate (4%), epicatechin (9%), epigallocatechin (23%), epicatechin gallate (12%), epigallocatechin gallate ( 41%) and others (4%). Moreover, leucine was used as (b) amino acids.
１０週齢のＳＡＭ−Ｐ１雄性マウス（老化促進モデルマウス）及びＳＡＭ−Ｒ１雄性マウス（通常老化マウス）を個別飼育にて５週間予備飼育した後、各系統の体重に差がないようにＳＡＭ−Ｒ１対照群、ＳＡＭ−Ｐ１対照群、ＳＡＭ−Ｐ１カテキン群、ＳＡＭ−Ｐ１ロイシン群、ＳＡＭ−Ｐ１カテキン／ロイシン併用群に群分けした（各群８匹）。表１に示す配合で調整した食餌を用いて９週間飼育した。尚，各マウスには流水プールを用い、１０ｍ／分の速度で３分間の運動を一日に５回、週に４日負荷した。 10 weeks old SAM-P1 male mice (aging promotion model mice) and SAM-R1 male mice (usually aging mice) were preliminarily raised for 5 weeks in individual breeding, and then SAM- so that there was no difference in the weight of each strain They were divided into R1 control group, SAM-P1 control group, SAM-P1 catechin group, SAM-P1 leucine group, and SAM-P1 catechin / leucine combination group (8 mice in each group). They were bred for 9 weeks using a diet adjusted according to the formulation shown in Table 1. A running water pool was used for each mouse, and exercise for 3 minutes at a speed of 10 m / min was applied 5 times a day and 4 days a week.
９週間飼育後に、マウスを解剖に供し、単離したヒラメ筋を３７℃のＫｒｅｂｓ溶液中（通気条件：９５％−酸素，５％−二酸化炭素）で、トランスデューサー（ＦＯＲＴ１００：Ｗｏｒｌｄ Ｐｒｅｃｉｓｉｏｎ Ｉｎｓｔｒｕｍｅｎｔｓ，Ｉｎｃ．）に固定した。その後、電気刺激（０．５ｍ秒、１４０Ｈｚ）を施し、最大筋力を測定した。筋力の測定結果を表２に示す。 After 9 weeks of breeding, the mice were dissected, and the isolated soleus muscle was placed in a Krebs solution at 37 ° C. (aeration conditions: 95% -oxygen, 5% -carbon dioxide) with a transducer (FORT100: World Precision Instruments, Inc.). )). Thereafter, electrical stimulation (0.5 ms, 140 Hz) was applied, and the maximum muscle strength was measured. The measurement results of muscle strength are shown in Table 2.
表２の結果から、老化促進モデルマウスであるＳＡＭ−Ｐ１対照群のヒラメ筋の最大筋力は通常老化マウスであるＳＡＭ−Ｒ１対照群に対して有意に減少しており、老化に伴い最大筋力は低下することがわかる。また、カテキン類あるいはロイシンを配合した飼料を摂取したマウスの最大筋力はＳＡＭ−Ｐ１対照群に対して有意な差は認められなかったのに対して、カテキン類とロイシンの併用は老化による筋力の低下を有意に抑制したことがわかる。
以上のことから、本発明のカテキン類／アミノ酸類の併用は老化に伴う筋力低下抑制剤として有用である。またＳＡＭ−Ｐ１対照群と比較し、カテキン／ロイシン併用群では筋力が向上したことから、カテキン／ロイシンの併用は運動機能の向上に有効である。
From the results of Table 2, the maximum muscle strength of the soleus muscle of the SAM-P1 control group, which is an aging promoting model mouse, is significantly decreased compared to the SAM-R1 control group, which is usually an aging mouse. It turns out that it falls. In addition, the maximum muscle strength of mice ingesting a diet containing catechins or leucine was not significantly different from that of the SAM-P1 control group, whereas the combined use of catechins and leucine produced muscle strength due to aging. It can be seen that the decrease was significantly suppressed.
From the above, the combined use of catechins / amino acids according to the present invention is useful as an inhibitor of muscle strength reduction accompanying aging. Moreover, since the muscular strength improved in the catechin / leucine combination group compared with the SAM-P1 control group, the combination of catechin / leucine is effective in improving the motor function.
試験例２ カテキン類及びアミノ酸類の筋肉萎縮抑制効果
カテキン類として、総カテキン量８１％の茶抽出物を用いた。また、カテキン類の組成は、ガロカテキン（７％）、ガロカテキンガレート（４％）、エピカテキン（９％）、エピガロカテキン（２３％）、エピカテキンガレート（１２％）、エピガロカテキンガレート（４１％）、その他（４％）であった。また、アミノ酸類として、ロイシンを用いた。
Test Example 2 Effects of catechins and amino acids on muscle atrophy A tea extract having a total catechin content of 81% was used as catechins. The composition of catechins is as follows: gallocatechin (7%), gallocatechin gallate (4%), epicatechin (9%), epigallocatechin (23%), epicatechin gallate (12%), epigallocatechin gallate ( 41%) and others (4%). Moreover, leucine was used as amino acids.
１３週齢のＳＡＭ−Ｐ１雄性マウス（老化促進モデルマウス）及びＳＡＭ−Ｒ１雄性マウス（通常老化マウス）を個別飼育にて５週間予備飼育した後、各系統の体重に差がないようにＳＡＭ−Ｒ１対照群、ＳＡＭ−Ｐ１対照群、ＳＡＭ−Ｐ１カテキン／ロイシン併用群に群分けした（各群８匹）。表３に示す配合で調整した食餌を用いて９週間飼育した。尚，各マウスには流水プールを用い、１０ｍ／分の速度で３分間の運動を一日に５回、週に４日負荷した。 After 13 weeks old SAM-P1 male mice (aging-promoting model mice) and SAM-R1 male mice (usually aging mice) were preliminarily raised for 5 weeks in individual breeding, SAM- They were divided into R1 control group, SAM-P1 control group, and SAM-P1 catechin / leucine combination group (8 mice in each group). Using the diet adjusted with the formulation shown in Table 3, it was raised for 9 weeks. A running water pool was used for each mouse, and exercise for 3 minutes at a speed of 10 m / min was applied 5 times a day and 4 days a week.
９週間飼育後に、マウスを解剖に供し、腓腹筋、ヒラメ筋、足底筋、長趾伸筋、大腿四頭筋を摘出した後、重量を測定し、総筋肉重量を求めた。体重当たりの総筋肉重量を表４に示す。 After rearing for 9 weeks, the mice were dissected and the gastrocnemius, soleus, plantar, long extensor, and quadriceps were removed, and the weight was measured to determine the total muscle weight. Table 4 shows the total muscle weight per body weight.
表４の結果から、老化促進モデルマウスであるＳＡＭ−Ｐ１対照群の体重に占める筋肉重量は通常老化マウスであるＳＡＭ−Ｒ１対照群に対して有意に減少しており、老化に伴い筋肉は萎縮することがわかる。また、カテキン類及びロイシンを配合した飼料を摂取したマウスの筋肉重量はＳＡＭ−Ｐ１対照群に対して有意に大きいことがわかる。
以上のことから、本発明のカテキン類／アミノ酸類の併用は老化に伴う筋萎縮抑制剤として有用である。
From the results in Table 4, the muscle weight in the body weight of the SAM-P1 control group, which is an aging-promoting model mouse, is significantly reduced compared to the SAM-R1 control group, which is usually an aging mouse. I understand that Moreover, it turns out that the muscle weight of the mouse | mouth which ingested the feed which mix | blended catechin and leucine is significantly larger than the SAM-P1 control group.
From the above, the combined use of catechins / amino acids of the present invention is useful as an inhibitor of muscle atrophy associated with aging.
調製例１（筋肉老化抑制用茶系飲料）
表５に示した配合及び条件で、本発明の筋肉老化抑制用アミノ酸配合茶系飲料を調製した。本飲料の保存安定性及び風味は良好であった。
Preparation Example 1 (tea-based beverage for inhibiting muscle aging)
With the formulation and conditions shown in Table 5, an amino acid-containing tea-based beverage for inhibiting muscle aging according to the present invention was prepared. The storage stability and flavor of this beverage were good.
調製例２（筋肉老化抑制用非茶系飲料）
表６に示した配合及び条件で、本発明の筋肉老化抑制用アミノ酸配合スポーツ飲料を調製した。本飲料の保存安定性及び風味は良好であった。
Preparation Example 2 (Non-tea drink for inhibiting muscle aging)
With the formulation and conditions shown in Table 6, an amino acid-containing sports drink for inhibiting muscle aging according to the present invention was prepared. The storage stability and flavor of this beverage were good.
調製例３（筋肉老化抑制用経腸栄養剤）
乳カゼイン３．４ｇ、分離大豆タンパク質１．６７ｇ、デキストリン１４．８６ｇ、ショ糖１．３ｇ、大豆油１．７５ｇ、シソ油０．１８ｇ、大豆リン脂質０．１４ｇ、グリセリン脂肪酸エステル０．０７ｇ、ミネラル類０．６０ｇ、ビタミン類０．０６ｇ、テアフラン９０ｓ（伊藤園）０．１１ｇ、ロイシン０．１８ｇ、イソロイシン０．０９ｇ、バリン０．０９ｇに精製水を加え、常法に従い、レトルト殺菌し、カテキン類及びアミノ酸類を含有する筋肉老化抑制用経腸栄養剤（１００ｍＬ）を得た。ミネラル類は、Ｎａ、Ｋ、Ｃａ、Ｍｇ、Ｐ、Ｃ１、Ｆｅなどの有機又は無機塩混合物、ビタミン類は、ビタミンＡ、Ｄ、Ｅ、ビタミンＢ1、Ｂ2、Ｂ6、Ｂ12、Ｃ、ナイアシン、パントテン酸などの混合物を
、国民栄養所要量に合致した量を用いた。
Preparation Example 3 (Enteral nutrient for inhibiting muscle aging)
Milk casein 3.4 g, isolated soy protein 1.67 g, dextrin 14.86 g, sucrose 1.3 g, soybean oil 1.75 g, perilla oil 0.18 g, soybean phospholipid 0.14 g, glycerin fatty acid ester 0.07 g, Purified water is added to 0.60 g of minerals, 0.06 g of vitamins, 0.11 g of theafuran 90s (Itoen), 0.18 g of leucine, 0.09 g of isoleucine, 0.09 g of valine, and sterilized by retort according to a conventional method. Enteral nutrient (100 mL) containing aging and amino acids was obtained. Minerals, Na, K, Ca, Mg , P, C1, organic or inorganic salt mixture, such as Fe, vitamins, vitamins A, D, E, vitamin B 1, B 2, B 6 , B 12, C A mixture of niacin, pantothenic acid, etc. was used in an amount consistent with national nutrition requirements.
調製例４（筋肉老化抑制用ゼリー食品）
カラギーナンとローカストビーンガムの混合ゲル化剤０．６５％、グレープフルーツの５０％の濃縮果汁５．０％、クエン酸０．０５％、ビタミンＣ０．０５％、テアビゴ（ＤＳＭニュートリショナル・プロダクツ）０．５４％、ロイシン０．３％、イソロイシン０．１５％、バリン０．１５％、タウリン０．５％を混合し、これに水を加えて１００％に調整し、６５℃で溶解した。更に少量のグレープフルーツフレーバーを添加して８５℃で５分間保持して殺菌処理後、１００ｍＬの容器に分注した。８時間静置して徐冷しながら５℃に冷却して、ゲル化させ、口に含んだ時に口溶け性が良好で、果実風味を有し食感良好なカテキン類及び分岐鎖アミノ酸を含有する筋肉老化抑制用ゼリー食品を得た。
Preparation Example 4 (Jelly food for inhibiting muscle aging)
Carrageenan and locust bean gum mixed gelling agent 0.65%, grapefruit 50% concentrated juice 5.0%, citric acid 0.05%, vitamin C 0.05%, theavigo (DSM Nutritional Products) 0. 54%, 0.3% leucine, 0.15% isoleucine, 0.15% valine and 0.5% taurine were mixed, adjusted to 100% with water and dissolved at 65 ° C. Further, a small amount of grapefruit flavor was added and kept at 85 ° C. for 5 minutes, sterilized, and dispensed into a 100 mL container. It is allowed to stand for 8 hours, slowly cooled to 5 ° C., gelled, and contains catechins and branched-chain amino acids that have good mouth meltability, fruit flavor, and texture when included in the mouth. A jelly food for inhibiting muscle aging was obtained.
調製例５（筋肉老化抑制用ビタミン内服液）
タウリン８００ｍｇ、ショ糖２０００ｍｇ、カラメル５０ｍｇ、安息香酸ナトリウム３０ｍｇ、ビタミンＢ1硝酸塩５ｍｇ、ビタミンＢ2 ２０ｍｇ、ビタミンＢ6 ２０ｍｇ、ビ
タミンＣ ２０００ｍｇ、ビタミンＥ １００ｍｇ、ビタミンＤ3 ２０００ＩＵ、ニコチン酸アミド２０ｍｇ、ポリフェノン７０Ｓ（三井農林）５０ｍｇ、ロイシン２００ｍｇ、イソロイシン１００ｍｇ、バリン１００ｍｇを適量の精製水に加えて溶解し、リン酸水溶液でｐＨ３に調節した後、更に精製水を加えて全量を５０ｍＬとした。これを８０℃で３０分滅菌して、カテキン類及びアミノ酸類を含有する筋肉老化抑制用飲料を得た。
Preparation Example 5 (Vitamin solution for inhibiting muscle aging)
Taurine 800 mg, sucrose 2000 mg, caramel 50 mg, sodium benzoate 30 mg, vitamin B 1 nitrate 5 mg, vitamin B 2 20 mg, vitamin B 6 20 mg, vitamin C 2000 mg, vitamin E 100 mg, vitamin D 3 2000 IU, nicotinamide 20 mg, polyphenone 70S (Mitsui Norin) 50 mg, leucine 200 mg, isoleucine 100 mg, and valine 100 mg were dissolved in an appropriate amount of purified water, adjusted to pH 3 with an aqueous phosphoric acid solution, and further purified water was added to make the total volume 50 mL. This was sterilized at 80 ° C. for 30 minutes to obtain a muscle aging-inhibiting beverage containing catechins and amino acids.
調製例６（筋肉老化抑制用チュアブル錠剤）
アスコルビン酸１８０ｍｇ、クエン酸５０ｍｇ、アスパルテーム１２ｍｇ、ステアリン酸マグネシウム２４ｍｇ、結晶セルロース１２０ｍｇ、乳糖２７４ｍｇ、テアフラン９０Ｓ（伊藤園）３００ｍｇ、ロイシン６００ｍｇ、イソロイシン３００ｍｇ、バリン３００ｍｇなる処方で、日本薬局方（製剤総則「錠剤」）に準じて錠剤を製造し、カテキン類及びアミノ酸類を含有する筋肉老化抑制用チュアブル錠剤を得た。
Preparation Example 6 (Chewable tablet for inhibiting muscle aging)
Ascorbic acid 180 mg, citric acid 50 mg, aspartame 12 mg, magnesium stearate 24 mg, crystalline cellulose 120 mg, lactose 274 mg, Tearfuran 90S (Itoen) 300 mg, leucine 600 mg, isoleucine 300 mg, valine 300 mg. ”) To produce a chewable tablet for inhibiting muscle aging containing catechins and amino acids.
調製例７（筋肉老化抑制用錠剤）
下記処方に基づいて、常法によりカテキン類及びアミノ酸類を含有する老化抑制用錠剤を調製した。成分配合量（重量％）：ポリフェノン７０Ｓ（三井農林）５、ロイシン１０、タウリン５、リンゴ酸ナトリウム２０、パラチノース２０、アスコルビン酸２０、ビタミンミックス５、結晶セルロース５、ショ糖エステル４、二酸化ケイ素１、卵殻カルシウム５。
Preparation Example 7 (Tablet for inhibiting muscle aging)
Based on the following formulation, an anti-aging tablet containing catechins and amino acids was prepared by a conventional method. Component blending amount (% by weight): Polyphenone 70S (Mitsui Norin) 5, Leucine 10, Taurine 5, Sodium malate 20, Palatinose 20, Ascorbic acid 20, Vitamin mix 5, Crystalline cellulose 5, Sucrose ester 4, Silicon dioxide 1 Eggshell calcium 5.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007186743A JP5507802B2 (en) | 2006-08-10 | 2007-07-18 | Muscle aging inhibitor |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006218140 | 2006-08-10 | ||
| JP2006218140 | 2006-08-10 | ||
| JP2007186743A JP5507802B2 (en) | 2006-08-10 | 2007-07-18 | Muscle aging inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008063321A true JP2008063321A (en) | 2008-03-21 |
| JP5507802B2 JP5507802B2 (en) | 2014-05-28 |
Family
ID=39286322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007186743A Active JP5507802B2 (en) | 2006-08-10 | 2007-07-18 | Muscle aging inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5507802B2 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012062309A (en) * | 2010-08-19 | 2012-03-29 | Nisshin Pharma Inc | Composition for muscular increase |
| WO2012165610A1 (en) * | 2011-06-03 | 2012-12-06 | 大正製薬株式会社 | Composition for maintaining or improving skin barrier function |
| JP2012250934A (en) * | 2011-06-03 | 2012-12-20 | Tokyo Univ Of Pharmacy & Life Science | Hyaluronic acid production promotor |
| JP2013091608A (en) * | 2011-10-25 | 2013-05-16 | Kao Corp | Myostatin/smad signal inhibitor |
| WO2014157153A1 (en) | 2013-03-28 | 2014-10-02 | 雪印メグミルク株式会社 | Muscle-atrophy-preventing agent |
| JP2016040315A (en) * | 2015-11-27 | 2016-03-24 | 大正製薬株式会社 | Hyaluronic acid production promoter |
| JP2016520050A (en) * | 2013-05-01 | 2016-07-11 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | How to enhance aging muscle regeneration |
| US9408410B2 (en) | 2012-03-08 | 2016-08-09 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US9682053B2 (en) | 2011-07-15 | 2017-06-20 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| US9707213B2 (en) | 2013-03-15 | 2017-07-18 | Nusirt Sciences, Inc. | Compositions, methods and kits for reducing lipid levels |
| US9724319B2 (en) | 2014-02-27 | 2017-08-08 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| US9943517B2 (en) | 2012-11-13 | 2018-04-17 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08169831A (en) * | 1994-12-16 | 1996-07-02 | Itouen:Kk | Agent for promoting metabolism of alcohol in body and its production |
| JPH0959154A (en) * | 1995-06-13 | 1997-03-04 | Itouen:Kk | Antidote |
| WO2001021186A1 (en) * | 1999-09-17 | 2001-03-29 | Otsuka Pharmaceutical Co., Ltd. | Compositions inhibiting muscle atrophy |
| JP2004331724A (en) * | 2003-04-30 | 2004-11-25 | Itochu Shiryo Kk | Antioxidant composition |
| WO2005104873A1 (en) * | 2004-04-28 | 2005-11-10 | Otsuka Pharmaceutical Co., Ltd. | Food containing amino acid |
| JP2005535617A (en) * | 2002-06-21 | 2005-11-24 | ロレアル | Use of taurine to treat alopecia |
| JP2006122004A (en) * | 2004-10-29 | 2006-05-18 | Kao Corp | Method for producing refined green tea extract |
| WO2006051980A1 (en) * | 2004-11-15 | 2006-05-18 | Kao Corporation | Packed beverage for lipid combustion promotion |
-
2007
- 2007-07-18 JP JP2007186743A patent/JP5507802B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08169831A (en) * | 1994-12-16 | 1996-07-02 | Itouen:Kk | Agent for promoting metabolism of alcohol in body and its production |
| JPH0959154A (en) * | 1995-06-13 | 1997-03-04 | Itouen:Kk | Antidote |
| WO2001021186A1 (en) * | 1999-09-17 | 2001-03-29 | Otsuka Pharmaceutical Co., Ltd. | Compositions inhibiting muscle atrophy |
| JP2005535617A (en) * | 2002-06-21 | 2005-11-24 | ロレアル | Use of taurine to treat alopecia |
| JP2004331724A (en) * | 2003-04-30 | 2004-11-25 | Itochu Shiryo Kk | Antioxidant composition |
| WO2005104873A1 (en) * | 2004-04-28 | 2005-11-10 | Otsuka Pharmaceutical Co., Ltd. | Food containing amino acid |
| JP2006122004A (en) * | 2004-10-29 | 2006-05-18 | Kao Corp | Method for producing refined green tea extract |
| WO2006051980A1 (en) * | 2004-11-15 | 2006-05-18 | Kao Corporation | Packed beverage for lipid combustion promotion |
Non-Patent Citations (2)
| Title |
|---|
| 佐藤真由美 外5名: "2C24p24『ロイシン投与による廃用性筋萎縮改善効果』", 日本農芸化学会大会講演要旨集, vol. 2006, JPN6012067409, 5 March 2006 (2006-03-05), JP, pages 136, ISSN: 0002417658 * |
| 長澤孝志 外5名: ""廃用性筋萎縮におけるロイシン投与が骨格筋分解と酸化ストレスに及ぼす影響"", 必須アミノ酸研究, JPN6012051181, March 2006 (2006-03-01), JP, pages 59 - 64, ISSN: 0002344327 * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012062309A (en) * | 2010-08-19 | 2012-03-29 | Nisshin Pharma Inc | Composition for muscular increase |
| JPWO2012165610A1 (en) * | 2011-06-03 | 2015-02-23 | 大正製薬株式会社 | Composition for maintaining or improving skin barrier function |
| WO2012165610A1 (en) * | 2011-06-03 | 2012-12-06 | 大正製薬株式会社 | Composition for maintaining or improving skin barrier function |
| JP2012250934A (en) * | 2011-06-03 | 2012-12-20 | Tokyo Univ Of Pharmacy & Life Science | Hyaluronic acid production promotor |
| US9682053B2 (en) | 2011-07-15 | 2017-06-20 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| US10383837B2 (en) | 2011-07-15 | 2019-08-20 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| US10076507B1 (en) | 2011-07-15 | 2018-09-18 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| US9855235B2 (en) | 2011-07-15 | 2018-01-02 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| JP2013091608A (en) * | 2011-10-25 | 2013-05-16 | Kao Corp | Myostatin/smad signal inhibitor |
| US9408410B2 (en) | 2012-03-08 | 2016-08-09 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US9901573B2 (en) | 2012-03-08 | 2018-02-27 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US9713609B2 (en) | 2012-03-08 | 2017-07-25 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US10646489B2 (en) | 2012-11-13 | 2020-05-12 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
| US9943517B2 (en) | 2012-11-13 | 2018-04-17 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
| US9707213B2 (en) | 2013-03-15 | 2017-07-18 | Nusirt Sciences, Inc. | Compositions, methods and kits for reducing lipid levels |
| US9895357B2 (en) | 2013-03-15 | 2018-02-20 | Nusirt Sciences, Inc. | Compositions, methods and kits for reducing lipid levels |
| WO2014157153A1 (en) | 2013-03-28 | 2014-10-02 | 雪印メグミルク株式会社 | Muscle-atrophy-preventing agent |
| JP2016520050A (en) * | 2013-05-01 | 2016-07-11 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | How to enhance aging muscle regeneration |
| US9872844B2 (en) | 2014-02-27 | 2018-01-23 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| US9724319B2 (en) | 2014-02-27 | 2017-08-08 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| JP2016040315A (en) * | 2015-11-27 | 2016-03-24 | 大正製薬株式会社 | Hyaluronic acid production promoter |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5507802B2 (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5507802B2 (en) | Muscle aging inhibitor | |
| US8962678B2 (en) | Senescence inhibitor | |
| CN101484158B (en) | Senescence inhibitor | |
| JP3592681B2 (en) | Packaged beverage | |
| US20120052138A1 (en) | Composition comprising green tea extract | |
| JP5110314B2 (en) | Sleep improving composition and sleep improving agent | |
| CN101484157B (en) | Agent for improving muscle power | |
| JP2008063318A (en) | Aging inhibitor | |
| EP1404351A1 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
| AU2002305703A1 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
| JP2008031148A (en) | Agent for improving muscle power | |
| JP4494033B2 (en) | Serum cholesterol lowering agent, food and drink, and method for producing the same | |
| JP5576694B2 (en) | GIP elevation inhibitor | |
| JP2010111608A (en) | Muscle damage inhibitor | |
| JP2004313189A (en) | Catechin containing food or drink and method for producing the same | |
| JP2011006355A (en) | Composition and food and drink for improving bone density | |
| KR20130119424A (en) | Ingredients derived from sphaeranthus indicus | |
| GB2548476A (en) | Composition for preventing or treating obesity containing alpha-lipoic acid and N-acetycysteine as active ingredients | |
| US20030017219A1 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
| JP5529417B2 (en) | Catechin-containing solid form food and drink | |
| JP2010275275A (en) | Composition for improving mental concentration ability and food/drink containing the same | |
| JP2009107994A (en) | Osteogenesis promoter | |
| WO2002096451A1 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
| JP2006104213A (en) | Food or drink used for lowering serum cholesterol and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100614 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140107 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140318 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140320 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 5507802 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |